Info

Sonus Pharmaceuticals, Inc. (Sonus) is focused on the development of cancer drugs. The Company has one drug in clinical development and two earlier stage programs. SN2310 Injectable Emulsion is being developed as a cancer therapy. As of December 31, 2007, Sonus ceased development activities for TOCOSOL Paclitaxel, a formulation of paclitaxel manufactured in a ready-to-use, injectable vitamin E-based emulsion formulation. During the year ended December 31, 2007, Sonus engaged Ferghana Partners Inc., an international provider of independent financial advisory services to firms in the biotechnology, pharmaceuticals, diagnostics and specialty chemicals industries, to assist the Company with these strategic alternatives.(Source: 10-K)